EP1545457A4 - Zelltransport-zusammensetzungen und ihre verwendungen - Google Patents

Zelltransport-zusammensetzungen und ihre verwendungen

Info

Publication number
EP1545457A4
EP1545457A4 EP03767137A EP03767137A EP1545457A4 EP 1545457 A4 EP1545457 A4 EP 1545457A4 EP 03767137 A EP03767137 A EP 03767137A EP 03767137 A EP03767137 A EP 03767137A EP 1545457 A4 EP1545457 A4 EP 1545457A4
Authority
EP
European Patent Office
Prior art keywords
cell transport
transport compositions
compositions
cell
transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03767137A
Other languages
English (en)
French (fr)
Other versions
EP1545457A2 (de
Inventor
Cohava Gelber
Kathleen Rousseau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Priority to EP11180288A priority Critical patent/EP2409686A1/de
Publication of EP1545457A2 publication Critical patent/EP1545457A2/de
Publication of EP1545457A4 publication Critical patent/EP1545457A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03767137A 2002-08-01 2003-08-01 Zelltransport-zusammensetzungen und ihre verwendungen Ceased EP1545457A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11180288A EP2409686A1 (de) 2002-08-01 2003-08-01 Zelltransport-Zusammensetzungen und ihre Verwendungen

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40015902P 2002-08-01 2002-08-01
US400159P 2002-08-01
US40652502P 2002-08-28 2002-08-28
US406525P 2002-08-28
US42738802P 2002-11-18 2002-11-18
US427388P 2002-11-18
US48919103P 2003-07-22 2003-07-22
US489191P 2003-07-22
PCT/US2003/024323 WO2004012672A2 (en) 2002-08-01 2003-08-01 Cell transport compositions and uses thereof

Publications (2)

Publication Number Publication Date
EP1545457A2 EP1545457A2 (de) 2005-06-29
EP1545457A4 true EP1545457A4 (de) 2009-07-01

Family

ID=31499552

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11180288A Withdrawn EP2409686A1 (de) 2002-08-01 2003-08-01 Zelltransport-Zusammensetzungen und ihre Verwendungen
EP03767137A Ceased EP1545457A4 (de) 2002-08-01 2003-08-01 Zelltransport-zusammensetzungen und ihre verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11180288A Withdrawn EP2409686A1 (de) 2002-08-01 2003-08-01 Zelltransport-Zusammensetzungen und ihre Verwendungen

Country Status (5)

Country Link
EP (2) EP2409686A1 (de)
JP (3) JP4828940B2 (de)
AU (1) AU2003257156B2 (de)
CA (1) CA2493478C (de)
WO (1) WO2004012672A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
WO2004012672A2 (en) * 2002-08-01 2004-02-12 Mannkind Corporation Cell transport compositions and uses thereof
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (de) 2006-02-22 2015-07-10 Mannkind Corp
KR101438839B1 (ko) * 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
WO2009055742A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Delivery of active agents
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018754A1 (en) * 1992-03-11 1993-09-30 Pharmaceutical Discovery Corporation Self-assembling diketopiperazine drug delivery system
WO2001000654A2 (en) * 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5877174A (en) 1994-12-01 1999-03-02 Toyama Chemical Co., Ltd. 2,3-diketopiperazine derivatives or their salts
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
BR9913284A (pt) * 1998-08-28 2001-05-15 Lilly Co Eli Métodos para administrar peptìdeos insulinotrópicos
WO2004012672A2 (en) * 2002-08-01 2004-02-12 Mannkind Corporation Cell transport compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018754A1 (en) * 1992-03-11 1993-09-30 Pharmaceutical Discovery Corporation Self-assembling diketopiperazine drug delivery system
WO2001000654A2 (en) * 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIM F ET AL: "MICROENCAPSULATION OF LIVING CELLS AND TISSUES", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 70, no. 4, 1 April 1981 (1981-04-01), pages 351 - 354, XP009003613, ISSN: 0022-3549, DOI: 10.1002/JPS.2600700402 *
PEZRON ISABELLE ET AL: "Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3).", JOURNAL OF PHARMACEUTICAL SCIENCES APR 2002, vol. 91, no. 4, April 2002 (2002-04-01), pages 1135 - 1146, XP002528202, ISSN: 0022-3549 *
STEINER S ET AL: "TechnosphereTM/Insulin: Proof of concept study with a new insulin formulation for pulmonary delivery", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES,, vol. 110, no. 1, 1 January 2002 (2002-01-01), pages 17 - 21, XP009161970 *

Also Published As

Publication number Publication date
WO2004012672A3 (en) 2004-08-05
CA2493478C (en) 2014-11-18
JP2006500961A (ja) 2006-01-12
CA2493478A1 (en) 2004-02-12
EP2409686A1 (de) 2012-01-25
AU2003257156B2 (en) 2007-08-30
WO2004012672A2 (en) 2004-02-12
AU2003257156A1 (en) 2004-02-23
JP2014074038A (ja) 2014-04-24
JP4828940B2 (ja) 2011-11-30
JP2011105730A (ja) 2011-06-02
EP1545457A2 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
EP1545457A4 (de) Zelltransport-zusammensetzungen und ihre verwendungen
EP1539941A4 (de) Adzyme und deren verwendungen
AU2003217350A8 (en) Proliferated cell lines and uses thereof
GB2386375B (en) Polymer electrolyte composition and uses thereof
IL164021A0 (en) Antibodies and anti-pharmaceutical compositions containing the same
IL166331A0 (en) 5-arylterazole compounds compositions thereof and uses therefor
GB0202059D0 (en) Chemical compositions and methods
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
AU2003266282A8 (en) Compositions comprising muscle progenitor cells and uses thereof
EP1501722A4 (de) Verbesserungen bei bugsprieten
AU2003240281A8 (en) Cell targeting methods and compositions
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003268078A8 (en) Levothyroxine compositions and methods
GB0207224D0 (en) Tenascin-W compositions and uses thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0325942D0 (en) Compositions and uses thereof
AU2003252164A8 (en) Insulin-producing cell compositions and related methods
TW549609U (en) Terminal and battery containing the same
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
GB0204871D0 (en) Load cell
AU2003216442A8 (en) Enkurin and uses thereof
GB0205277D0 (en) Azetidinium-functionalised polymer and compositions containing the same
GB0202783D0 (en) Granule and composition containing same
GB0210495D0 (en) Improvements in compositions
GB0203356D0 (en) Compounds compositions and uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050301

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MANNKIND CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROUSSEAU, KATHLEEN

Inventor name: GELBER, COHAVA

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20090519BHEP

Ipc: A61K 9/14 20060101ALI20090519BHEP

Ipc: A61K 9/12 20060101AFI20050223BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090602

17Q First examination report despatched

Effective date: 20090907

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROUSSEAU, KATHLEEN

Inventor name: GELBER, COHAVA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MANNKIND CORPORATION

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160214